阶梯医疗再获5亿融资：阿里腾讯均已下注的脑机接口企业，近一年融资超11亿元

Core Viewpoint - Shanghai Ladder Medical Technology Co., Ltd. has completed a strategic financing of 500 million yuan, led by Alibaba, marking a significant milestone in the brain-machine interface (BMI) sector, with expectations to surpass Neuralink's clinical trial numbers by the end of 2026 [2][4][7]. Group 1: Financing and Investment - Ladder Medical has raised over 1.1 billion yuan in total financing over the past year, becoming the first company in the BMI field backed by Alibaba and Tencent [4]. - The recent financing round included participation from several prominent investors, indicating strong confidence in the company's potential [2][4]. Group 2: Technological Advancements - Founded in 2021, Ladder Medical focuses on minimally invasive BMI technology, having developed leading technologies in electrodes, systems, algorithms, and surgical robots [4]. - The company has successfully completed clinical trials for a 256-channel wireless high-throughput invasive BMI system, marking a significant technological leap and the first of its kind in China [6][7]. Group 3: Clinical Progress and Future Plans - Ladder Medical plans to conduct large-scale multi-center registration clinical trials in mid-2026, aiming to enroll approximately 40 patients within the year [7]. - By the end of 2026, the total number of clinical implants is expected to approach or exceed Neuralink's current total of about 21 cases, positioning Ladder Medical as a leader in the commercialization and clinical application of BMI technology [7]. Group 4: Strategic Partnerships and Market Position - The involvement of major tech companies like Alibaba and Tencent is seen as a milestone, enhancing the integration of life sciences and information technology in the BMI sector [9]. - Ladder Medical's advancements align with national strategic plans, establishing it as a core innovative force in China's BMI strategy [9].